Tags

Type your tag names separated by a space and hit enter

[Drug Repositioning for Alzheimer's Disease].
Brain Nerve 2019; 71(9):961-970BN

Abstract

To date, all clinical trials of disease-modifying drugs for Alzheimer's disease (AD) have been unsuccessful, making investments into AD drug development very risky despite the high unmet need. Drug repositioning or repurposing approaches are relatively less expensive and more promising compared to novel drug development in AD. About 40% of clinical trials for AD currently in progress across the world use the drug repositioning method. They are expected to be a trigger for AD drug discovery that breaks the current deadlock situation. By using drugs approved for other indications, these clinical trials target dysregulated pathways of AD with different or a combination of modes of action, including anti-amyloid, anti-tau, anti-inflammatory, metabolic, neuroprotective, and neurotransmission-based approaches. In these clinical trials, cardiovascular drugs such as insulin, cilostazol, probucol, telmisartan, and dabigatran are tested for their effect on different mechanisms of AD pathology. This is in line with the recent emphasis that AD should be studied as a complex multifactorial disorder, not dominated by one dominant biological factor such as beta-amyloid, and without disregarding any relevant pathologic factor, such as vascular dysregulation. It is strongly expected that drug repositioning approaches will create a paradigm shift in treatment approaches for AD patients.

Authors+Show Affiliations

Department of Neurology, National Cerebral and Cardiovascular Center.No affiliation info available

Pub Type(s)

Journal Article

Language

jpn

PubMed ID

31506398

Citation

Ihara, Masafumi, and Satoshi Saito. "[Drug Repositioning for Alzheimer's Disease]." Brain and Nerve = Shinkei Kenkyu No Shinpo, vol. 71, no. 9, 2019, pp. 961-970.
Ihara M, Saito S. [Drug Repositioning for Alzheimer's Disease]. Brain Nerve. 2019;71(9):961-970.
Ihara, M., & Saito, S. (2019). [Drug Repositioning for Alzheimer's Disease]. Brain and Nerve = Shinkei Kenkyu No Shinpo, 71(9), pp. 961-970. doi:10.11477/mf.1416201388.
Ihara M, Saito S. [Drug Repositioning for Alzheimer's Disease]. Brain Nerve. 2019;71(9):961-970. PubMed PMID: 31506398.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Drug Repositioning for Alzheimer's Disease]. AU - Ihara,Masafumi, AU - Saito,Satoshi, PY - 2019/9/12/entrez PY - 2019/9/12/pubmed PY - 2019/9/20/medline SP - 961 EP - 970 JF - Brain and nerve = Shinkei kenkyu no shinpo JO - Brain Nerve VL - 71 IS - 9 N2 - To date, all clinical trials of disease-modifying drugs for Alzheimer's disease (AD) have been unsuccessful, making investments into AD drug development very risky despite the high unmet need. Drug repositioning or repurposing approaches are relatively less expensive and more promising compared to novel drug development in AD. About 40% of clinical trials for AD currently in progress across the world use the drug repositioning method. They are expected to be a trigger for AD drug discovery that breaks the current deadlock situation. By using drugs approved for other indications, these clinical trials target dysregulated pathways of AD with different or a combination of modes of action, including anti-amyloid, anti-tau, anti-inflammatory, metabolic, neuroprotective, and neurotransmission-based approaches. In these clinical trials, cardiovascular drugs such as insulin, cilostazol, probucol, telmisartan, and dabigatran are tested for their effect on different mechanisms of AD pathology. This is in line with the recent emphasis that AD should be studied as a complex multifactorial disorder, not dominated by one dominant biological factor such as beta-amyloid, and without disregarding any relevant pathologic factor, such as vascular dysregulation. It is strongly expected that drug repositioning approaches will create a paradigm shift in treatment approaches for AD patients. SN - 1881-6096 UR - https://www.unboundmedicine.com/medline/citation/31506398/[Drug_Repositioning_for_Alzheimer's_Disease] L2 - https://webview.isho.jp/openurl?rft.genre=article&rft.issn=1881-6096&rft.volume=71&rft.issue=9&rft.spage=961 DB - PRIME DP - Unbound Medicine ER -